• Medical_Professionals
• Medical_students
• Nurses

ARROWHEAD’S ANNUAL PAIN & MIGRAINE THERAPEUTICS SUMMIT is the US’s premier pain conference covering the field of pain research and therapeutics. Leaders from the pharmaceutical, biotech, device and medical communities attend this conference to learn about the latest advances in the treatment of various types of pain and to network with colleagues from industry, the non-profit sector, academia, the medical community, government and investors.

This conference provides attendees with thoughtful insight from key industry leaders and academic researchers concerning cutting edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies and newly marketed products. We will highlight the most important developments in recent years in the field, including new research in genome-wide association studies, CGRP antagonists, NGF antagonists, sodium and calcium channel blockers, new research in biologic therapies, the genetic components of pain, abuse-resistant opioids, analysis of FDA’s REMS program and a plethora of other topics.

Key Themes

Analysis of new drug discovery targets

Real-time fMRI (functional magnetic resonance imaging) for pain

Analysis of NGF antagonist clinical development programs

Exploration and analysis of animal models for pain

Gene therapy for pain

Sodium and calcium channel blockers in pre-clinical & clinical development

Challenges of pain clinical trials

Endpoints in pain clinical trials

Molecular tools for dissecting pain pathways

Abuse-resistant opioids in clinical development

Clinical development status of longer-acting analgesics for post-operative pain

Review and analysis of key developmental stage therapies for nociceptive pain, neuropathic pain, migraine, back pain, fibromyalgia, cancer pain, arthritic pain, acute pain and chronic pain

The future role of pharmacogenomics, biomarkers and translational research in the development of therapeutics for pain

Analysis and case studies of successful commercialization strategies for pain therapies

Genome-wide association studies of pain

USD

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

Submission Info

The 9th Annual Pain & Migraine Therapeutics Summit Poster Session provides the opportunity for individuals to present their research and offers an excellent venue for extended informal discussion with meeting attendees.

Requirements
Abstracts should be no longer than 1000 words and follow a standard format (background, methods, results, and conclusion). Please include the following in your submission:

• Full name and affiliation
• Poster title
• Abstract

Deadlines/Other information
Please email your submission to John Waslif at john.waslif@paintherapeuticsummit.comby September 6, 2015. If you have questions, please email us or call 866-945-0263 ext. 700.

Guidelines for Presenters
Information regarding physical dimensions/specifications for accepted submissions will be communicated to presenters via email.

* Regular registration rates apply for all accepted poster session presenters

Past Poster Presentations

Clinical Evaluation of Tampering: Oxycodone DETERx® Versus OxyContin

Ernest Kopecky, Ph.D., Collegium Pharmaceutical

Rapid-acting Novel Small Peptide Peripherally-Restricted Kappa Opioid Agonists for the Treatment of Pain

Joseph Guarneri, MannKind Corporation

Novel Mu Opioid Mechanisms for the Potent Analgesic Cyt-1010 Distinguish it from Morphine

Theodore Malone, Ph.D, Cytogel Pharma

A Novel Non-Opioid Analgesic Displays Efficacy in Models of Inflammatory, Neuropathic and Cancer Pain

Jean Lachowicz, Ph.D., Chief Scientific Officer, Angiochem

Itching to Advance Nav1.7 Small Molecule Inhibitors to the Clinic

Kristen Taborn, M.S., Amgen

The Impact of Implementing a National Research Subject Database to Prevent Dual Enrollment in Early and Late Phase Central Nervous System Trials Mitchell Efros, M.D., Verified Clinical Trials

A Novel Formulation of Sublingual Ketamine with Consistent Bioavailability

Paul Rolan, Professor of Clinical Pharmacology, University of Adelaide

Nocipoint Therapy - Eliminates the Chronic Pain and Restores Functions Permanently and Rapidly

Charles Koo, Visiting Scholar, Stanford University

A Phase 1b Study to Investigate PL37, the First Dual Enkephalinase Inhibitor (DENKI), in Two Experimental Human Pain Models

Klaus Francke, Global Medical Affairs Consultant, PAREXEL International

First Demonstration of the Neuroimmune Link in Humans Using IV Endotoxin and Intradermal Capsaicin the Face and Arm

Paul Rolan, Professor of Clinical Pharmacology, University of Adelaide

A Novel Prolonged Pro-liposomal Local Anesthetic Formulation for Post Operative Pain management

Michael Naveh, Chief Operating Officer, Pain Reform Ltd.

Efficacy of Anti-LPA Antibody Therapy in Neuropathic Pain

Rosalia Matteo, Senior Scientist, Lpath, Inc.

A Novel Anti-inflammatory and Analgesic Molecule Which is GI-, Renal-, and Platelet-sparing

Jeremy Blitzer, Partner & VP Product Development, Synergenics, LLC

Comparison of the Crush Resistant Properties of Oxycodone DETERx, a Multiparticulate, Extended-release, Tamper Resistant Formulation Versus a Currently Marketed Oxycodone Extended-release Product

Ernest Kopecky, VP, Clinical Development | Head, Neuroscience TA, COLLEGIUM Pharmaceutical

Transdermal Delivery of Cannabinoid and Opiate Prodrugs for Pain Treatment

Audra Stinchcomb, Ph.D., Chief Scientific Officer, AllTranz

Plasma and Cerebrospinal Fluid Pharmacokinetic Parameters after Single-Dose Administration of Intravenous, Oral or Rectal Acetaminophen

Mike Royal, MD VP Clinical Development & Medical Affairs, Cadence Pharmaceuticals

Neil Singla, MD, CEO, Lotus Clinical Research

Identification of a Non-opioid Analgesic Candidate VVZ-149, Selective to Three Pain Targets, GlyT2, 5HT2A and P2X3, with Moderate Potency

Pang Min-hee, Ph.D., Senior Researcher, VizoZon, Inc.

Sunyoung Cho, Ph.D., Research Director, VivoZon, Inc.

Analgesic Properties of S-Etifoxine and β-Subunit Selective Modulators of GABAA Receptors

Tim Johnstone, Ph.D., Research Specialist, UC Irvine

BL-1021: A New Chemical Entity for the Treatment of Neuropathic Pain

Yotam Nisemblat, M.Sc., Senior Drug Development Manager, BioLineRx

A New Class of Pain Therapeutics - ddRNAi Gene Constructs

Peter French, Ph.D., Chief Executive Officer, Benitec Limited

High Throughput Automated Behavioral Assessment for Enhanced Translation in Analgesic Drug Discovery

David Lowe, Ph.D., Chief Scientific Officer, PsychoGenics

Vince & Associates Clinical Research’s State-of-the-Art, 90-bed Clinical Pharmacology Unit and purpose-built Outpatient Research Center allows our company to quickly and effectively conduct clinical trials from Analgesia to Abuse Liability.

For general information about the conference, please contact us at:

  queries@paintherapeuticsummit.com

  +866.945.0263

  +866.945.0263

  5780 Lincoln Drive, Suite 205, Edina, Minnesota 55436 USA